Short answer: Most thyroid cancers cannot be detected or ruled out with a routine blood test. Thyroid-stimulating hormone (TSH) and thyroid hormone levels are often normal even when cancer is present. A thyroid-cancer diagnosis generally depends on a medical history and neck examination, thyroid ultrasound, fine-needle aspiration (FNA) with cytology when indicated, and sometimes surgical pathology. Blood tests have narrower, phase-specific roles: they can evaluate thyroid function, support selected evaluation for medullary thyroid cancer, and help monitor certain cancers after treatment.
For a broader explanation of thyroid hormones, antibodies, and test patterns, see Thyroid Blood Tests: TSH, Free T4, Free T3, and Thyroid Antibodies. For the limitations of tumor markers across cancer types, see Cancer Blood Tests and Tumor Markers: Uses, Limits, and Next Steps.
The thyroid is a butterfly-shaped gland in the lower front of the neck. It makes hormones that help regulate energy use, temperature, heart rate, and many other body functions. Thyroid cancer begins when cells in the gland grow abnormally and form a malignant tumor.
The major categories behave differently:
The cancer type matters because it determines which imaging, pathology, molecular tests, treatments, and follow-up biomarkers may be useful. A test that helps monitor differentiated thyroid cancer may not be useful for MTC, and the reverse is also true.
Many thyroid cancers are found before they cause symptoms—during a neck examination, after a person notices a lump, or incidentally on imaging obtained for another reason. Most thyroid nodules are benign, but symptoms and ultrasound findings determine what should happen next.
| Symptom or finding | Why it matters | What to do |
|---|---|---|
| A new lump or nodule low in the front of the neck | The most common presentation; most nodules are not cancer | Arrange a clinical neck examination. Ultrasound may be appropriate. |
| A lump that is enlarging or feels firm/fixed | Growth or fixation can increase concern, although benign conditions can also enlarge | Seek timely professional evaluation; do not wait for a blood panel to clarify it. |
| Enlarged lymph nodes in the neck | Can occur with infection or inflammation, but may also accompany thyroid cancer | Have persistent, enlarging, hard, or unexplained nodes assessed. |
| Persistent hoarseness or a change in voice | May reflect vocal-cord irritation or nerve involvement, but common noncancer causes exist | Seek evaluation if the change persists, especially with a neck mass. |
| Trouble swallowing or a pressure sensation | A larger thyroid nodule, goiter, or another neck condition can compress nearby structures | Arrange prompt assessment, particularly if symptoms are progressing. |
| Shortness of breath, noisy breathing, or rapidly increasing neck swelling | May indicate airway compression or another urgent problem | Seek urgent or emergency care. |
| Persistent neck, throat, jaw, or ear pain without a clear cause | Less common and nonspecific, but should be assessed if persistent | Discuss it with a health professional, especially if a mass is present. |
| Persistent cough not explained by a respiratory illness | Usually has a nonthyroid cause, but can merit evaluation when paired with a neck mass or voice change | Seek a clinical assessment rather than relying on thyroid blood tests. |
Symptoms cannot tell whether a thyroid nodule is benign or malignant. Benign nodules, goiter, thyroiditis, cysts, reflux, respiratory illness, and many other conditions can cause overlapping symptoms. Conversely, a small thyroid cancer may cause no symptoms at all.
Call emergency services or seek urgent care for new or worsening breathing difficulty, noisy breathing, inability to swallow liquids or saliva, or rapidly expanding neck swelling. These symptoms can threaten the airway and should not be delayed while waiting for laboratory results.
Arrange prompt, non-emergency evaluation for a growing neck mass, persistent hoarseness, unexplained enlarged neck lymph nodes, or progressive swallowing difficulty. A primary care clinician, endocrinologist, otolaryngologist, or thyroid surgeon may coordinate the evaluation.
For most papillary, follicular, and oncocytic thyroid cancers, no. There is no routine blood test that can reliably screen for, diagnose, or exclude these cancers. TSH and thyroid hormones may remain within the laboratory reference interval because a structural tumor can be present while the gland continues to make a normal amount of hormone.
This distinction is fundamental:
A normal function test answers a function question. It does not answer a cancer question.
A health professional asks when a lump or symptom began, whether it is changing, and whether there is a history of childhood head or neck radiation, thyroid cancer in the family, MTC, MEN2, or a known hereditary syndrome. The examination assesses the thyroid, the movement and character of a nodule, cervical lymph nodes, and signs of airway or voice involvement.
Ultrasound is the key structural test for a suspected thyroid nodule. It evaluates the nodule's size and features—such as composition, echogenicity, shape, margins, and calcifications—and surveys nearby lymph nodes. Systems such as ACR TI-RADS help standardize risk description and recommendations.
Ultrasound estimates risk; it does not by itself prove that a nodule is cancer. The combination of sonographic pattern, size, clinical history, and lymph-node findings helps determine whether observation or FNA is appropriate. Learn more in Thyroid Nodules Explained: A Complete Guide.
If a nodule meets clinical and ultrasound criteria, a clinician may recommend ultrasound-guided FNA. A thin needle removes cells for a pathologist to examine. Cytology may be benign, malignant, suspicious, nondiagnostic, or indeterminate.
An indeterminate result does not mean cancer. Repeat FNA, molecular analysis, continued surveillance, or diagnostic surgery may be considered depending on the cytology category, ultrasound pattern, nodule size, personal risk, local expertise, and patient preferences.
Some thyroid cancers—particularly follicular-pattern tumors—cannot be classified with certainty from cytology alone because diagnosis may depend on whether tumor cells invade the capsule or blood vessels. Examination of surgically removed tissue may therefore be necessary for a definitive diagnosis and complete risk assessment.
CT, MRI, nuclear imaging, laryngoscopy, or molecular testing may be appropriate in selected situations. These are not automatic tests for every thyroid nodule. The care team chooses them based on symptoms, ultrasound and cytology findings, suspected cancer type, and whether disease outside the thyroid must be evaluated.
Routine thyroid-cancer screening is not recommended for asymptomatic, average-risk adults. The U.S. Preventive Services Task Force concludes that screening in this population produces harms that outweigh the benefits. Those harms can include false-positive results, unnecessary procedures, and treatment of very small cancers that might never have caused illness.
This recommendation does not mean that a new lump, enlarged lymph node, persistent voice change, or swallowing problem should be ignored. It also does not apply in the same way to people with a known high-risk hereditary syndrome or certain radiation exposures. Symptoms and high-risk histories require individualized professional evaluation.
Factors that can increase risk or change the evaluation include:
Most people who develop thyroid cancer do not have a clearly identifiable cause. Having a risk factor does not prove cancer, and lacking one does not rule it out.
| Blood test | What it can help assess | What it cannot establish |
|---|---|---|
| TSH Test | Thyroid-pituitary regulation; helps determine whether a nodule is associated with normal, low, or high thyroid function | Whether a nodule is benign or malignant; a normal TSH does not rule out cancer |
| T4 Free Test | The unbound portion of thyroxine; interpreted with TSH to assess thyroid function | The presence, type, stage, or absence of thyroid cancer |
| Thyroglobulin Panel Test | Thyroglobulin (Tg) plus thyroglobulin antibodies (TgAb); primarily supports follow-up of selected differentiated thyroid cancers after treatment | Initial cancer screening or diagnosis when a thyroid gland remains in place |
| Calcitonin Test | Selected evaluation and follow-up for MTC or C-cell disease; interpretation belongs in clinical context | General screening for all thyroid cancers or a stand-alone MTC diagnosis |
| CEA Test | Baseline and trend monitoring in confirmed or strongly suspected MTC, generally with calcitonin | Screening for or diagnosing thyroid cancer; CEA is nonspecific and may rise for noncancer reasons |
| RET germline testing | Identifies an inherited RET variant associated with hereditary MTC/MEN2 and can guide relatives' care | Whether an ordinary thyroid nodule is malignant; it is not a general thyroid-cancer blood screen |
Ulta currently has direct-access pages for the five linked blood tests above. RET germline testing for suspected hereditary MTC should be arranged through an endocrinologist, genetics professional, or specialized cancer service so that pretest counseling, test selection, family implications, and follow-up are handled appropriately.
The TSH Test is commonly part of the initial evaluation of a thyroid nodule because it indicates how the thyroid-pituitary system is functioning. A low TSH may lead a clinician to consider radionuclide imaging to determine whether a nodule is autonomously functioning. A high or normal TSH is interpreted with the history, examination, and ultrasound.
The T4 Free Test may be added when the clinical question involves thyroid hormone status. These results help identify hypothyroidism, hyperthyroidism, or other function patterns, but they cannot characterize a nodule's cells. People with thyroid cancer commonly have normal thyroid-function results.
Thyroglobulin is made by normal thyroid follicular cells and by many differentiated thyroid-cancer cells. While the thyroid gland remains, a Tg result cannot reliably separate normal thyroid tissue, benign thyroid disease, and cancer. For this reason, thyroglobulin is not an appropriate general screening or initial diagnostic test for thyroid cancer.
After total thyroidectomy—with or without radioactive iodine, depending on the treatment plan—serial Tg may become useful. A low or undetectable result can be reassuring in the proper setting, while a rising trend may prompt additional evaluation. The result must be interpreted alongside the extent of surgery, time since treatment, TSH level, prior results, pathology, imaging, and the assay used.
The Thyroglobulin Panel Test includes TgAb because these antibodies can interfere with Tg measurement. A Tg value should not be interpreted without checking the antibody result. When monitoring over time, consistency in laboratory and method can make trends more interpretable.
MTC begins in C cells, which produce calcitonin. The Calcitonin Test can support evaluation when MTC is suspected from FNA, pathology, symptoms, family history, or a known hereditary syndrome. It is also an important marker after MTC treatment. A falling or very low postoperative value may support a favorable response; a persistent or rising trend may lead the care team to investigate residual or recurrent disease.
Calcitonin is not a universal screening test. MTC is uncommon, test results vary by method and clinical context, and elevations can occur with C-cell hyperplasia, certain medicines, pregnancy, and other noncancer conditions. A normal value may not completely exclude MTC. Interpretation belongs with an endocrinologist or thyroid-cancer team when the concern is substantial.
The CEA Test is generally used with calcitonin in confirmed or strongly suspected MTC and during follow-up. CEA is not specific to thyroid cancer: several cancers and noncancerous conditions can raise it, and some cancers do not produce it. Smoking can also affect CEA. The direction and pace of change over time are usually more informative than an isolated result.
Some MTC is caused by a hereditary pathogenic variant in the RET gene. Professional guidance recommends genetic counseling and germline RET testing for people diagnosed with MTC, with appropriate testing and counseling for at-risk relatives when a hereditary variant is found.
This testing has consequences for the individual and family, including children, and can change the timing of preventive or therapeutic care. It should be selected and interpreted through a qualified clinical genetics or endocrine team. Tumor-only molecular findings and inherited germline findings are not the same; a genetics professional can explain the distinction.
The same test name can have a very different meaning at different points in care.
| Phase | Main question | Tests that usually answer it |
|---|---|---|
| A neck lump or suspected nodule | Is there a structural abnormality, and how suspicious is it? | Examination and ultrasound; TSH helps assess function but not malignancy |
| A nodule that meets biopsy criteria | What do the cells show? | Ultrasound-guided FNA with cytology; selected molecular testing if indeterminate |
| A possible or confirmed cancer | What type is it, how extensive is it, and what treatment is appropriate? | Pathology, neck imaging, selected additional imaging or molecular tests; calcitonin/CEA for MTC when indicated |
| Follow-up after differentiated thyroid cancer | Is there evidence of persistent or recurrent disease, and is thyroid-hormone therapy on target? | Clinical examination, neck ultrasound, Tg with TgAb, TSH, and selected imaging according to risk |
| Follow-up after MTC | Is there biochemical or structural evidence of disease? | Calcitonin and CEA trends, examination, ultrasound, and additional imaging when indicated |
A bundled thyroid or tumor-marker panel cannot collapse these phases into one answer. Testing should begin with a defined question and a plan for what an abnormal, normal, or indeterminate result will trigger.
Preparation depends on the exact assay and reason for testing. Use the instructions supplied with the selected test and tell the ordering clinician and laboratory about medications, supplements, pregnancy, smoking, recent procedures, and prior thyroid treatment.
For a practical guide to flags, units, trends, and reference intervals, see How to Read and Understand Your Lab Results.
An out-of-range result is a starting point, not a diagnosis. Ask:
The Complete Guide to Lab Tests and Blood Work explains how laboratory testing fits into a broader clinical decision rather than standing alone.
Direct-access testing can help answer a defined laboratory question, track a clinician-recommended marker, or provide results for a scheduled medical visit. Direct-Access Lab Testing: How It Works and What to Expect explains the process and limitations.
It should not delay examination of a neck lump, ultrasound, FNA, or urgent care for breathing or swallowing symptoms. Before ordering a marker, know why it is being measured and who will interpret it. Thyroglobulin, calcitonin, and CEA can create false reassurance or unnecessary alarm when used outside the clinical settings in which they are informative.
No. There is no single blood test that reliably finds or rules out all thyroid cancers. TSH and Free T4 evaluate hormone function. Ultrasound evaluates structure, and FNA examines cells. Thyroglobulin is mainly a post-treatment marker for selected differentiated cancers, while calcitonin and CEA have narrower roles in medullary thyroid cancer.
Yes. TSH is often normal in people with thyroid cancer because a nodule can be malignant without changing overall hormone production. A normal TSH may be useful information about thyroid function, but it cannot establish whether a lump is benign or malignant. Suspicious symptoms or a nodule still need structural evaluation.
A clinician generally starts with a history and neck examination. Thyroid and neck ultrasound is the main imaging test used to characterize a nodule and nearby lymph nodes. TSH is often measured to assess function, but it does not replace ultrasound. The ultrasound pattern and size help determine whether FNA or surveillance is appropriate.
Ultrasound can identify features associated with higher or lower malignancy risk, but it cannot always distinguish cancer from a benign nodule. It guides decisions about FNA and helps target the sample. Cytology and, in some cases, surgical pathology are needed to establish the diagnosis and cancer type.
No. Many nodules are small or have low-risk ultrasound features and can be monitored. FNA decisions depend on the sonographic pattern, nodule size, lymph nodes, symptoms, history, and professional guidelines. Avoiding unnecessary biopsy is part of good care, just as promptly sampling a suspicious nodule is.
No. Normal thyroid tissue, benign thyroid disease, and many differentiated thyroid cancers can all contribute to thyroglobulin while a thyroid gland remains. Tg becomes most useful in defined follow-up after treatment, especially after total thyroidectomy. Results must be interpreted with TgAb, TSH, treatment history, imaging, and previous trends.
TgAb can interfere with thyroglobulin assays and make the Tg value misleading. Measuring both helps the care team judge whether Tg is reliable and whether antibody trends provide additional context. A positive TgAb result does not itself diagnose cancer; antibodies are also seen in autoimmune thyroid disease.
Not necessarily. Practice varies, and calcitonin is most clearly useful when MTC is suspected, confirmed, associated with a hereditary risk, or being monitored after treatment. Because MTC is uncommon and calcitonin can be elevated for noncancer reasons, test selection and follow-up should be individualized.
No. CEA is nonspecific and cannot diagnose MTC by itself. It is generally interpreted with calcitonin, FNA or pathology, imaging, and clinical history in people with suspected or confirmed MTC. Its trend may help monitor treatment response or recurrence, but smoking and noncancerous conditions can affect the result.
People diagnosed with MTC should receive genetics-guided assessment for germline RET testing. At-risk relatives may need counseling and targeted testing if a hereditary variant is found. Because results can affect relatives and preventive care, testing should be arranged through an endocrinology or genetics service, not treated as a general wellness screen.
No. Blood testing can assess function or support a defined monitoring plan, but it cannot show a nodule's structure or examine its cells. If you have a lump, suspicious lymph node, persistent voice change, or swallowing problem, professional evaluation is the appropriate next step even when blood results are normal.
Follow up with a health professional. Normal TSH, Free T4, or tumor-marker results cannot exclude all structural thyroid disease or thyroid cancer. Persistent or progressive symptoms may require neck examination, ultrasound, evaluation of the vocal cords or swallowing, or assessment for a nonthyroid cause.
Thyroid cancer is primarily a structural and pathologic diagnosis—not a routine blood-test diagnosis. A new neck lump, enlarging lymph node, persistent hoarseness, or swallowing difficulty should lead to clinical evaluation. Ultrasound and, when indicated, FNA or surgical pathology determine whether a nodule is malignant.
Blood tests are valuable when they answer the right question. TSH and Free T4 evaluate function. Thyroglobulin with TgAb supports selected monitoring after differentiated thyroid-cancer treatment. Calcitonin and CEA support selected MTC evaluation and follow-up. None should be used as a stand-alone shortcut around examination, imaging, biopsy, or specialist care.
This article is for education and does not diagnose, treat, or replace advice from a qualified health professional. Laboratory results must be interpreted with symptoms, examination, imaging, pathology, treatment history, medications, and other clinical information. Ulta Lab Tests provides direct-access laboratory testing and may receive revenue when tests are purchased through its website. Ordering a test should not delay urgent care or professional evaluation of a neck mass or other concerning symptom.
Originally published: October 30, 2024 | Substantively updated: September 1 2026
These tests help determine how the thyroid is functioning. They cannot determine whether a nodule is cancerous.
These are essential to the diagnostic pathway but are not direct-access blood tests:
Ulta Lab Tests, LLC.
9237 E Via de Ventura, Suite 220
Scottsdale, AZ 85258
480-681-4081
(Toll Free: 800-714-0424)
